Impacto económico de la vacuna antirrotavirus en Panamá

Translated title of the contribution: Economic impact of rotavirus vaccination in Panama

Dagna Constenla, E. Ortega-Barría, R. D. Rheingans, L. Antil, X. Sáez-Llorens

Research output: Contribution to journalArticle

Abstract

Introduction: Rotavirus (RV) gastroenteritis (GE) causes a significant health and economic burden in Panama. The main objective of this study is to estimate the healthcare costs and the cost-effectiveness of vaccination in Panama from the societal perspective. Methods: An economic model was constructed, using published epidemiological data, country-specific cost estimates, and vaccine efficacy data. The main outcome measures were disease burden, economic burden and the incremental cost-effectiveness ratio (US$/DALY and US$/life saved) of vaccination. Results: In Panama, among children during the first five years of life, it is estimated that due to RV GE, 283 per 1,000 have a clinic visit, 24 per 1,000 are hospitalized, and 0.53 per 1,000 die. For every 1,000 children born, RV infection results in US$16,463 in total costs during their first five years of life. An estimated US$862,388 may be spent annually on treatment of outpatient and hospitalized cases in Panama. Vaccination would prevent 65 % of the associated deaths, 68 % of hospitalizations, 69 % of outpatient visits and 65 % of associated DALY (Disability Adjusted Life Years). From the societal perspective, RV vaccination produces a cost-effectiveness ratio of US$487 per DALY when the price of the vaccine is US$7.50 per dose. Conclusions: Vaccination can effectively reduce the disease burden and healthcare costs of RV GE in Panama.

Original languageSpanish
Pages (from-to)128-135
Number of pages8
JournalAnales de Pediatria
Volume68
Issue number2
DOIs
StatePublished - Feb 1 2008
Externally publishedYes

Fingerprint

Panama
Rotavirus
Vaccination
Economics
Quality-Adjusted Life Years
Gastroenteritis
Cost-Benefit Analysis
Cost of Illness
Health Care Costs
Outpatients
Vaccines
Economic Models
Rotavirus Infections
Costs and Cost Analysis
Ambulatory Care
Hospitalization
Outcome Assessment (Health Care)
Health

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Constenla, D., Ortega-Barría, E., Rheingans, R. D., Antil, L., & Sáez-Llorens, X. (2008). Impacto económico de la vacuna antirrotavirus en Panamá. Anales de Pediatria, 68(2), 128-135. https://doi.org/10.1157/13116227

Impacto económico de la vacuna antirrotavirus en Panamá. / Constenla, Dagna; Ortega-Barría, E.; Rheingans, R. D.; Antil, L.; Sáez-Llorens, X.

In: Anales de Pediatria, Vol. 68, No. 2, 01.02.2008, p. 128-135.

Research output: Contribution to journalArticle

Constenla, D, Ortega-Barría, E, Rheingans, RD, Antil, L & Sáez-Llorens, X 2008, 'Impacto económico de la vacuna antirrotavirus en Panamá', Anales de Pediatria, vol. 68, no. 2, pp. 128-135. https://doi.org/10.1157/13116227
Constenla D, Ortega-Barría E, Rheingans RD, Antil L, Sáez-Llorens X. Impacto económico de la vacuna antirrotavirus en Panamá. Anales de Pediatria. 2008 Feb 1;68(2):128-135. https://doi.org/10.1157/13116227
Constenla, Dagna ; Ortega-Barría, E. ; Rheingans, R. D. ; Antil, L. ; Sáez-Llorens, X. / Impacto económico de la vacuna antirrotavirus en Panamá. In: Anales de Pediatria. 2008 ; Vol. 68, No. 2. pp. 128-135.
@article{20734a72b2f74d49be6988626243a9cc,
title = "Impacto econ{\'o}mico de la vacuna antirrotavirus en Panam{\'a}",
abstract = "Introduction: Rotavirus (RV) gastroenteritis (GE) causes a significant health and economic burden in Panama. The main objective of this study is to estimate the healthcare costs and the cost-effectiveness of vaccination in Panama from the societal perspective. Methods: An economic model was constructed, using published epidemiological data, country-specific cost estimates, and vaccine efficacy data. The main outcome measures were disease burden, economic burden and the incremental cost-effectiveness ratio (US$/DALY and US$/life saved) of vaccination. Results: In Panama, among children during the first five years of life, it is estimated that due to RV GE, 283 per 1,000 have a clinic visit, 24 per 1,000 are hospitalized, and 0.53 per 1,000 die. For every 1,000 children born, RV infection results in US$16,463 in total costs during their first five years of life. An estimated US$862,388 may be spent annually on treatment of outpatient and hospitalized cases in Panama. Vaccination would prevent 65 {\%} of the associated deaths, 68 {\%} of hospitalizations, 69 {\%} of outpatient visits and 65 {\%} of associated DALY (Disability Adjusted Life Years). From the societal perspective, RV vaccination produces a cost-effectiveness ratio of US$487 per DALY when the price of the vaccine is US$7.50 per dose. Conclusions: Vaccination can effectively reduce the disease burden and healthcare costs of RV GE in Panama.",
author = "Dagna Constenla and E. Ortega-Barr{\'i}a and Rheingans, {R. D.} and L. Antil and X. S{\'a}ez-Llorens",
year = "2008",
month = "2",
day = "1",
doi = "10.1157/13116227",
language = "Spanish",
volume = "68",
pages = "128--135",
journal = "Anales de Pediatria",
issn = "1695-4033",
publisher = "Ediciones Doyma, S.L.",
number = "2",

}

TY - JOUR

T1 - Impacto económico de la vacuna antirrotavirus en Panamá

AU - Constenla, Dagna

AU - Ortega-Barría, E.

AU - Rheingans, R. D.

AU - Antil, L.

AU - Sáez-Llorens, X.

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Introduction: Rotavirus (RV) gastroenteritis (GE) causes a significant health and economic burden in Panama. The main objective of this study is to estimate the healthcare costs and the cost-effectiveness of vaccination in Panama from the societal perspective. Methods: An economic model was constructed, using published epidemiological data, country-specific cost estimates, and vaccine efficacy data. The main outcome measures were disease burden, economic burden and the incremental cost-effectiveness ratio (US$/DALY and US$/life saved) of vaccination. Results: In Panama, among children during the first five years of life, it is estimated that due to RV GE, 283 per 1,000 have a clinic visit, 24 per 1,000 are hospitalized, and 0.53 per 1,000 die. For every 1,000 children born, RV infection results in US$16,463 in total costs during their first five years of life. An estimated US$862,388 may be spent annually on treatment of outpatient and hospitalized cases in Panama. Vaccination would prevent 65 % of the associated deaths, 68 % of hospitalizations, 69 % of outpatient visits and 65 % of associated DALY (Disability Adjusted Life Years). From the societal perspective, RV vaccination produces a cost-effectiveness ratio of US$487 per DALY when the price of the vaccine is US$7.50 per dose. Conclusions: Vaccination can effectively reduce the disease burden and healthcare costs of RV GE in Panama.

AB - Introduction: Rotavirus (RV) gastroenteritis (GE) causes a significant health and economic burden in Panama. The main objective of this study is to estimate the healthcare costs and the cost-effectiveness of vaccination in Panama from the societal perspective. Methods: An economic model was constructed, using published epidemiological data, country-specific cost estimates, and vaccine efficacy data. The main outcome measures were disease burden, economic burden and the incremental cost-effectiveness ratio (US$/DALY and US$/life saved) of vaccination. Results: In Panama, among children during the first five years of life, it is estimated that due to RV GE, 283 per 1,000 have a clinic visit, 24 per 1,000 are hospitalized, and 0.53 per 1,000 die. For every 1,000 children born, RV infection results in US$16,463 in total costs during their first five years of life. An estimated US$862,388 may be spent annually on treatment of outpatient and hospitalized cases in Panama. Vaccination would prevent 65 % of the associated deaths, 68 % of hospitalizations, 69 % of outpatient visits and 65 % of associated DALY (Disability Adjusted Life Years). From the societal perspective, RV vaccination produces a cost-effectiveness ratio of US$487 per DALY when the price of the vaccine is US$7.50 per dose. Conclusions: Vaccination can effectively reduce the disease burden and healthcare costs of RV GE in Panama.

UR - http://www.scopus.com/inward/record.url?scp=40549107437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40549107437&partnerID=8YFLogxK

U2 - 10.1157/13116227

DO - 10.1157/13116227

M3 - Article

C2 - 18341878

AN - SCOPUS:40549107437

VL - 68

SP - 128

EP - 135

JO - Anales de Pediatria

JF - Anales de Pediatria

SN - 1695-4033

IS - 2

ER -